• IDE397 (MAT2A inhibitor): A drug candidate targeting MTAP-deletion solid tumors.
• IDE161 (PARG inhibitor): An investigational therapy for homologous recombination deficient (HRD) or other PARG-sensitive tumors.
• IDEAX002 (WRN inhibitor): A preclinical program focused on treating high microsatellite instability (MSI-high) solid tumors.
• Darovasertib (PKC inhibitor): A clinical-stage product in collaboration with GSK for the treatment of uveal melanoma.
• GSK616 (CDK8/19 inhibitor): An investigational drug candidate in collaboration with GSK for tumors with specific genetic alterations.

IDEAYA Biosciences (IDYA) is a biotechnology company focused on the discovery and development of precision oncology medicines. As is typical for a biotech company in the development stage, IDEAYA Biosciences primarily sells or partners with other companies rather than directly to individuals.

Its major customer is:

• GSK plc (NYSE: GSK)

IDEAYA has a global strategic collaboration agreement with GSK plc to develop and commercialize several of its synthetic lethality programs, including IDE397 (MAT2A inhibitor) and other programs (Werner Helicase, Pol Theta). This collaboration involves upfront payments, milestone payments, and potential royalties, which represent the primary source of collaboration revenue for IDEAYA Biosciences.

• Lonza Group Ltd (LONN.SW)
• Evonik Industries AG (EVK.DE)

Yujiro S. Hata, President and Chief Executive Officer

Yujiro S. Hata founded IDEAYA Biosciences in June 2015 as its first employee and led the company's IPO on NASDAQ in May 2019. He is an entrepreneur with 30 years of experience building companies that have delivered innovative therapies to patients. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, which he led through its acquisition by Bristol-Myers Squibb in April 2015. He then served as Chief Operating Officer at FLX Bio (renamed RAPT Therapeutics), a spinout of Flexus Biosciences. From 2010 to 2014, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, which was acquired by Amgen in October 2013. He also served as Vice President, Senior Vice President, and Chief Business Officer at Enanta Pharmaceuticals from 2002 to 2010. From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures.

Joshua Bleharski, Chief Financial Officer

Joshua Bleharski joined IDEAYA Biosciences as Chief Financial Officer in May 2025. Prior to IDEAYA, he spent nearly 17 years with J.P. Morgan, where he was a Managing Director and Global Co-Head of Biopharma within the Healthcare Investment Banking group. During his banking career, he advised on deals representing more than $65 billion of value, with a focus on capital markets transactions, mergers and acquisitions, and corporate strategy. Earlier in his career, he worked as a Senior Staff Scientist at a private biotechnology company in San Diego.

Darrin M. Beaupre, Chief Medical Officer

Darrin M. Beaupre is a Medical Oncologist and Hematologist with 16 years of industry experience in both early and late-phase clinical development. He previously served as the Chief Medical Officer in Oncology at Biosplice, where he oversaw the Oncology Research and Development Therapeutic area. Before that, he was Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer.

Daniel A. Simon, Chief Business Officer

Daniel A. Simon joined IDEAYA Biosciences in August 2024 and leads the company's business development and strategy. He has over 20 years of experience on the business side of lifesciences. From 2022 to 2024, he was Chief Business Officer at Revolution Medicines, overseeing portfolio strategy and valuation, competitive intelligence, and commercialization. From 2015 to 2022, he served as Senior Vice President, leading BioPharma Business Development at Guardant Health.

Paul A. Barsanti, Chief Technology Officer

Paul A. Barsanti joined IDEAYA as Vice President, Head of Drug Discovery in November 2019 and is currently the Chief Technology Officer. He is responsible for medicinal chemistry, computational chemistry, structural biology, and preclinical activities. Dr. Barsanti previously served as an Executive in Residence at 5AM Ventures. His prior roles include Director, Head of Chemical Sciences at Nurix, and various positions at Novartis, including Associate Director and Group Leader.

IDEAYA Biosciences (IDYA) focuses on precision medicine oncology with a pipeline of targeted therapies. The addressable markets for its main products are as follows:

• Darovasertib (IDE196): This PKC inhibitor targets uveal melanoma (UM), including metastatic uveal melanoma (MUM) and primary uveal melanoma (UM).
  • The annual incidence of uveal melanoma in the U.S. is estimated to be between 2,000 and 3,000 patients.
  • The global uveal melanoma treatment market size is projected to reach approximately $3.22 billion by the end of 2034.
• IDE397: This MAT2A inhibitor is developed for patients with tumors having an MTAP gene deletion.
  • MTAP gene deletion is estimated to occur in approximately 15% of all solid tumors.
  • The global solid tumor market is projected to reach $283.8 billion by 2029, implying a potential addressable market of $42.6 billion globally for IDE397.
  • In the U.S., the estimated annual incidence rate for MTAP-deleted solid tumors is approximately 75,000 patients. For urothelial cancer (UC) and non-small cell lung cancer (NSCLC) with MTAP deletion, the estimated U.S. annual incidence is approximately 48,000 patients.
• IDE161: This PARG inhibitor targets tumors with homologous recombination deficiency (HRD), including ER+, Her2-, HRD breast cancer, HRD ovarian cancer, and endometrial cancer.
  • GlobalData's Expiry Model projects IDE-161 revenue to reach an annual total of $93 million by 2036 globally. However, a definitive addressable market size for the condition it treats is not explicitly provided.
• IDE705 (GSK101): A Pol Theta Helicase Inhibitor for HRD solid tumors.
  • Addressable Market: null
• Werner Helicase Inhibitors (IDE275/GSK959): These target tumors with high microsatellite instability (MSI-High).
  • Addressable Market: null
• IDE849 (SHR-4849): A DLL3 TOP1i Antibody Drug Conjugate for small cell lung cancer (SCLC) and neuroendocrine tumors (NETs).
  • Addressable Market: null

Expected Drivers of Future Revenue Growth for IDEAYA Biosciences (IDYA)

Over the next 2-3 years, IDEAYA Biosciences (IDYA) is expected to drive future revenue growth through several key areas:

1. Strategic Partnerships and Collaboration Revenue: A significant driver of recent and anticipated future revenue is IDEAYA's ability to secure and advance strategic partnerships. For instance, the company recently received a substantial upfront payment of $210 million from Servier for the exclusive licensing rights to its lead drug candidate, darovasertib, outside the United States. Such collaborations provide critical funding, share development risks, and can lead to future milestone payments and royalties as pipeline assets progress towards commercialization globally.
2. Advancement and Potential Commercialization of Darovasertib: Darovasertib is IDEAYA's lead drug candidate, and its progress is a crucial revenue driver. The company anticipates reporting median progression-free survival (PFS) data from the Phase 2/3 trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line HLA*A2-negative metastatic uveal melanoma between year-end 2025 and Q1 2026. Positive data from this trial has the potential to enable an accelerated approval filing in the United States, paving the way for commercialization and product-based revenue.
3. Progression of a Deep Pipeline of Oncology Candidates: Beyond darovasertib, IDEAYA boasts a deep pipeline of precision medicine oncology candidates, many of which are focused on synthetic lethality and antibody-drug conjugates (ADCs). These include IDE397, IDE849, IDE161, IDE275 (GSK959), and IDE705 (GSK101). Several of these programs are in various stages of clinical development, with some being advanced through collaborations with GlaxoSmithKline (GSK). Successful clinical development and eventual commercialization of these additional pipeline assets represent significant opportunities for long-term revenue growth.
4. Data Readouts and Milestones from Clinical Programs: The company has a "catalyst-rich period" with multiple clinical data updates expected across its three clinical-stage programs. Positive data readouts, such as the 21.1-month median overall survival data observed in a Phase 2 trial of the darovasertib/crizotinib combination, can increase the value of its assets, attract further investment, and potentially trigger milestone payments from partners, contributing to revenue growth.

1. Share Issuance

   • On October 30, 2025, IDEAYA Biosciences granted non-qualified stock options for 73,500 shares to two newly hired employees under its 2023 Inducement Plan, with an exercise price of $25.69 per share.
   • On October 25, 2025, non-qualified stock options were granted to a new employee to purchase 31,400 shares of common stock under the 2023 Employment Inducement Incentive Award Plan, also at an exercise price of $25.69 per share.
   • In August 2024, an S-8 filing indicated securities offered to employees pursuant to employee benefit plans.

2. Inbound Investments

   • In September 2025, IDEAYA entered into an exclusive license agreement with Servier for darovasertib rights outside the United States, receiving an upfront payment of $210 million. The agreement also includes eligibility for up to $100 million in regulatory approval-based milestone payments and up to $220 million in commercial milestone payments, along with double-digit royalties on net sales outside the US.
   • In June 2020, IDEAYA established a strategic partnership with GlaxoSmithKline (GSK) for its Synthetic Lethality programs. This partnership included an upfront cash payment of $100 million and a $20 million equity purchase of IDEAYA common stock via a direct private placement.

3. Outbound Investments

   • In January (presumably 2025), IDEAYA paid Hengrui Pharmaceuticals $75 million upfront to acquire rights to a DLL3-directed antibody-drug conjugate outside of greater China.
   • IDEAYA Biosciences reported $0.0 in long-term investments for the last 12-month period ending in 2024.